FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088417966> ?p ?o ?g. }

• W2088417966 endingPage "202" @default.
• W2088417966 startingPage "185" @default.
• W2088417966 abstract "Despite the considerable clinical, radiologic, and functional benefits of biologic inhibitors in inflammatory arthritides, some concern exists regarding the occurrence of infections in patients treated with these agents. Clearly, comorbidities such as diabetes mellitus, heart disease, disability, and concurrent immunosuppressive medication all contribute to the risk of infection. Increased and closer observation may be in part responsible for some of the reported increases in the rates of mild infections with these drugs. The development of serious infections, particularly TB, in patients taking infliximab seems to be greater than would be expected in this population. Furthermore, experimental data from in vitro investigations and animal models demonstrate a link between decreased TNF alpha activity and increased susceptibility to TB. Why some patients, but not others, succumb to rapidly disseminated infection is unknown but may be related to the extent of TNF inhibition in different individuals. This difference in inhibition may also explain why the incidence of TB seems to be increased with infliximab in comparison with the other TNF blockers. Attribution analysis is the method used to assess the likelihood of a connection between two occurrences and includes such factors as temporal association, few alternative explanations, analogy with similar cases, and biologic plausibility. The putative relationship between anti-TNF treatment and infection is further strengthened by the presence of these factors [101]. Continued vigilance is therefore required in the use of biologic agents in patients with RA, most of whom are already in some way immunocompromised. Everyone who is under consideration for such treatment should be carefully evaluated for the presence of infection, and prophylactic antituberculous therapy should be used if latent TB is discovered. Both patients and primary physicians need to be aware of the possibility that serious infection may develop; if such a problem is diagnosed, the biologic inhibitor should be discontinued until adequate treatment has been completed. Caution is advised in patients with recurring infections and in those with severe comorbidities, for example, poorly controlled diabetes mellitus or heart failure. Administration of live vaccines to patients taking these drugs is not recommended, but patients should be brought up-to-date with all immunizations relevant to their age group before commencement of therapy. Physicians prescribing biologic agents should be encouraged to report any suspected drug-related adverse event. Long-term observation will be required to determine the exact nature of the relationship between cytokine inhibition and infection." @default.
• W2088417966 created "2016-06-24" @default.
• W2088417966 creator A5022630337 @default.
• W2088417966 creator A5045703102 @default.
• W2088417966 date "2003-02-01" @default.
• W2088417966 modified "2023-09-27" @default.
• W2088417966 title "Infection complications associated with the use of biologic agents" @default.
• W2088417966 cites W132781887 @default.
• W2088417966 cites W1515994079 @default.
• W2088417966 cites W1521095043 @default.
• W2088417966 cites W1523015364 @default.
• W2088417966 cites W180072684 @default.
• W2088417966 cites W1963868638 @default.
• W2088417966 cites W1973123086 @default.
• W2088417966 cites W1973645860 @default.
• W2088417966 cites W1974903457 @default.
• W2088417966 cites W1976424171 @default.
• W2088417966 cites W1978103379 @default.
• W2088417966 cites W1980978904 @default.
• W2088417966 cites W1996472975 @default.
• W2088417966 cites W1998253405 @default.
• W2088417966 cites W2006154561 @default.
• W2088417966 cites W2007830806 @default.
• W2088417966 cites W2011437322 @default.
• W2088417966 cites W2018410379 @default.
• W2088417966 cites W2020339300 @default.
• W2088417966 cites W2021659381 @default.
• W2088417966 cites W2023809975 @default.
• W2088417966 cites W2024418426 @default.
• W2088417966 cites W2026254148 @default.
• W2088417966 cites W2030353584 @default.
• W2088417966 cites W2032140498 @default.
• W2088417966 cites W2034165765 @default.
• W2088417966 cites W2035538567 @default.
• W2088417966 cites W2038535814 @default.
• W2088417966 cites W2043287930 @default.
• W2088417966 cites W2050154180 @default.
• W2088417966 cites W2052747333 @default.
• W2088417966 cites W2056813079 @default.
• W2088417966 cites W2057123987 @default.
• W2088417966 cites W2060471737 @default.
• W2088417966 cites W2064370469 @default.
• W2088417966 cites W2067420120 @default.
• W2088417966 cites W2072738451 @default.
• W2088417966 cites W2073205223 @default.
• W2088417966 cites W2073598149 @default.
• W2088417966 cites W2074631683 @default.
• W2088417966 cites W2081833623 @default.
• W2088417966 cites W2085486418 @default.
• W2088417966 cites W2091651459 @default.
• W2088417966 cites W2091732273 @default.
• W2088417966 cites W2093296844 @default.
• W2088417966 cites W2094313417 @default.
• W2088417966 cites W2098546846 @default.
• W2088417966 cites W2098767548 @default.
• W2088417966 cites W2100936707 @default.
• W2088417966 cites W2103854548 @default.
• W2088417966 cites W2107350019 @default.
• W2088417966 cites W2128938421 @default.
• W2088417966 cites W2129974845 @default.
• W2088417966 cites W2141912213 @default.
• W2088417966 cites W2142273705 @default.
• W2088417966 cites W2144152742 @default.
• W2088417966 cites W2145481747 @default.
• W2088417966 cites W2151365647 @default.
• W2088417966 cites W2156243671 @default.
• W2088417966 cites W2158329969 @default.
• W2088417966 cites W2165599181 @default.
• W2088417966 cites W2166837261 @default.
• W2088417966 cites W2167031471 @default.
• W2088417966 cites W2168698481 @default.
• W2088417966 cites W2312982528 @default.
• W2088417966 cites W2314052274 @default.
• W2088417966 cites W2319957449 @default.
• W2088417966 cites W2325491525 @default.
• W2088417966 cites W2326330820 @default.
• W2088417966 cites W2328587823 @default.
• W2088417966 cites W2340084730 @default.
• W2088417966 cites W2414735972 @default.
• W2088417966 doi "https://doi.org/10.1016/s0889-857x(02)00101-1" @default.
• W2088417966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12635507" @default.
• W2088417966 hasPublicationYear "2003" @default.
• W2088417966 type Work @default.
• W2088417966 sameAs 2088417966 @default.
• W2088417966 citedByCount "110" @default.
• W2088417966 countsByYear W20884179662012 @default.
• W2088417966 countsByYear W20884179662013 @default.
• W2088417966 countsByYear W20884179662014 @default.
• W2088417966 countsByYear W20884179662015 @default.
• W2088417966 countsByYear W20884179662016 @default.
• W2088417966 countsByYear W20884179662017 @default.
• W2088417966 countsByYear W20884179662018 @default.
• W2088417966 countsByYear W20884179662019 @default.
• W2088417966 countsByYear W20884179662020 @default.
• W2088417966 countsByYear W20884179662022 @default.
• W2088417966 crossrefType "journal-article" @default.
• W2088417966 hasAuthorship W2088417966A5022630337 @default.
• W2088417966 hasAuthorship W2088417966A5045703102 @default.

• next